226 related articles for article (PubMed ID: 31839722)
1. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations.
Margetić S; Ćelap I; Delić Brkljačić D; Pavlović N; Šupraha Goreta S; Kobasić I; Lovrenčić-Huzjan A; Bašić Kes V
Biochem Med (Zagreb); 2020 Feb; 30(1):010702. PubMed ID: 31839722
[TBL] [Abstract][Full Text] [Related]
2. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
[TBL] [Abstract][Full Text] [Related]
3. Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay for measurement of direct oral Xa inhibitors in ex vivo patient samples.
Lim MS; Hayes R; Sharma A; Kitiponchai T; Mohamed M; Mcrae S
Pathology; 2022 Aug; 54(5):599-605. PubMed ID: 35414442
[TBL] [Abstract][Full Text] [Related]
4. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
[TBL] [Abstract][Full Text] [Related]
5. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays.
Hillarp A; Gustafsson KM; Faxälv L; Strandberg K; Baghaei F; Fagerberg Blixter I; Berndtsson M; Lindahl TL
J Thromb Haemost; 2014 Sep; 12(9):1545-53. PubMed ID: 24965851
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
[TBL] [Abstract][Full Text] [Related]
8. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
[TBL] [Abstract][Full Text] [Related]
9. Anti-factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors.
Stuart M; Johnson L; Hanigan S; Pipe SW; Li SH
J Thromb Haemost; 2020 Jul; 18(7):1653-1660. PubMed ID: 32216028
[TBL] [Abstract][Full Text] [Related]
10. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
[TBL] [Abstract][Full Text] [Related]
11. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
Cini M; Legnani C; Padrini R; Cosmi B; Dellanoce C; De Rosa G; Marcucci R; Pengo V; Poli D; Testa S; Palareti G
Int J Lab Hematol; 2020 Apr; 42(2):214-222. PubMed ID: 32039550
[TBL] [Abstract][Full Text] [Related]
12. A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation.
Willekens G; Studt JD; Mendez A; Alberio L; Fontana P; Wuillemin WA; Schmidt A; Graf L; Gerber B; Bovet C; Sauter TC; Nagler M
Br J Haematol; 2021 Jun; 193(6):1203-1212. PubMed ID: 33954979
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Commercial Low Molecular Weight Heparin and Homemade Anti-Xa Calibrators to a Commercial Specific Anti-Xa Calibrator for Plasma Rivaroxaban Quantification by Anti-Xa Oral Anticoagulant Plasma Concentration Chromogenic Assay.
Divsalar B; Kalantari T; Mohebbi S; Bahmanimehr A; Shahsavani A; Borhani-Haghighi A
Lab Med; 2023 Jul; 54(4):400-405. PubMed ID: 36573788
[TBL] [Abstract][Full Text] [Related]
14. Activated Factor X-Based versus Thrombin-Based Antithrombin Testing in Thrombophilia Workup in the DOAC Era.
Rühl H; Reda S; Müller J; Oldenburg J; Pötzsch B
Thromb Haemost; 2018 Feb; 118(2):381-387. PubMed ID: 29378360
[TBL] [Abstract][Full Text] [Related]
15. Practical Nomogram Predicting Apixaban or Rivaroxaban Concentrations from Low-Molecular-Weight Heparin Anti-Xa Values: Special Interest in Acute Ischemic Stroke Patients.
Brakta C; Stépanian A; Reiner P; Delrue M; Mazighi M; Curis E; Siguret V
J Stroke; 2023 Jan; 25(1):126-131. PubMed ID: 36592965
[TBL] [Abstract][Full Text] [Related]
16. An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.
Cini M; Legnani C; Testa S; Tripodi A; Cosmi B; Palareti G
Int J Lab Hematol; 2019 Jun; 41(3):309-315. PubMed ID: 30698331
[TBL] [Abstract][Full Text] [Related]
17. Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?
Yates SG; Smith S; Tharpe W; Shen YM; Sarode R
Transfus Apher Sci; 2016 Oct; 55(2):212-215. PubMed ID: 27377884
[TBL] [Abstract][Full Text] [Related]
18. Assessment of low plasma concentrations of apixaban in the periprocedural setting.
Lessire S; Dincq AS; Siriez R; Pochet L; Sennesael AL; Vornicu O; Hardy M; Deceuninck O; Douxfils J; Mullier F
Int J Lab Hematol; 2020 Aug; 42(4):394-402. PubMed ID: 32297711
[TBL] [Abstract][Full Text] [Related]
19. Heparin Anti-Xa Activity, a Readily Available Unique Test to Quantify Apixaban, Rivaroxaban, Fondaparinux, and Danaparoid Levels.
Boissier E; Senage T; Babuty A; Gouin-Thibault I; Rozec B; Roussel JC; Sigaud M; Ternisien C; Trossaert M; Fouassier M; Lakhal K
Anesth Analg; 2021 Mar; 132(3):707-716. PubMed ID: 32833716
[TBL] [Abstract][Full Text] [Related]
20. Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak-Trough Levels in an Asian Population: A Multicenter Study.
Liu Z; Xie Q; Zhang H; Mu G; Zhou S; Wang Z; Jiang J; Xiang Q; Cui Y
Am J Cardiovasc Drugs; 2021 Nov; 21(6):669-679. PubMed ID: 34142346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]